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Abstract 
Background: Regular monitoring of HIV patients who are receiving antiretroviral therapy (ART) is required to ensure 
patient benefits and the long-term effectiveness and sustainability of ART programs. Prompted by WHO recom-
mendations for expansion and decentralization of HIV treatment and care in low and middle income countries, we 
conducted a systematic review to assess the feasibility of treatment monitoring in these settings.
Methods: A comprehensive search strategy was developed using a combination of MeSH and free text terms 
relevant to HIV treatment and care, health service delivery, health service accessibility, decentralization and other 
relevant terms. Five electronic databases and two conference websites were searched to identify relevant studies con-
ducted in LMICs, published in English between Jan 2006 and Dec 2015. Outcomes of interest included the proportion 
of patients who received treatment monitoring and health system factors related to monitoring of patients on ART 
under decentralized HIV service delivery models.
Results: From 5363 records retrieved, twenty studies were included in the review; all but one was conducted in sub-
Saharan African countries. The majority of studies (15/20) had relatively short follow-up duration (≤24 months), and 
only two studies were specifically designed to assess treatment monitoring practices. The most frequently studied 
follow-up period was 12 months and a wide range of treatment monitoring coverage was observed. The reported 
proportions of patients on ART who received CD4 monitoring ranged from very low (6%; N = 2145) to very high (95%; 
N = 488). The median uptake of viral load monitoring was 86% with studies in program settings reporting coverage as 
low as 14%. Overall, the longer the follow-up period, the lower the proportion of patients who received regular moni-
toring tests; and programs in rural areas reported low coverage of laboratory monitoring. Moreover, uptake in the 
context of research had significantly better where monitoring was done by dedicated research staff. In the absence 
of point of care (POC) testing, the limited capacity for blood sample transportation between clinic and laboratory and 
poor quality of nursing staff were identified as a major barrier for treatment monitoring practice.
Conclusions: There is a paucity of data on the uptake of treatment monitoring, particularly with longer-term follow-
up. Wide variation in access to both virological and immunological regular monitoring was observed, with some 
clinics in well-resourced settings supported by external donors achieving high coverage. The feasibility of treatment 
monitoring, particularly in decentralized settings of HIV treatment and care may thus be of concern and requires fur-
ther study. Significant investment in POC diagnostic technologies and, improving the quality of and training for nurs-
ing staff is required to ensure effective scale up of ART programs towards the targets of 90-90-90 by the year 2020.
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Background
Increasing access to antiretroviral therapy (ART) for peo-
ple living with HIV/AIDS has been identified as a key 
strategy to curb the HIV epidemic and avoid its cost in 
the future [1]. In 2015, an estimated 15 million people 
living with HIV/AIDS (PLWHs) were receiving ART, a 
remarkable milestone in the fight against HIV/AIDS [2]. 
However, in order to achieve the ambitious sustainable 
development goal of ending the HIV epidemic by 2030, 
greater efforts are required in expanding ART coverage 
and improving quality of services with innovative and 
effective service delivery models.
In a number of the low and middle income countries 
(LMICs) most affected by the epidemic, decentralization 
of HIV treatment and care, linked with task-shifting, has 
been implemented in response to the need for scaling up 
service provision [3]. Evidence from existing systematic 
reviews suggests that relocation of ART services closer to 
patients’ homes through decentralized care can improve 
patient access and adherence to HIV treatment with non-
inferior quality of care as compared to centralized, hospi-
tal-based care [4–6].
Current WHO guidelines on the use of ARV drugs 
for HIV treatment and prevention strongly recommend 
virological monitoring as the strategy of choice for moni-
toring responses to ART [7]. Immunological monitoring 
(CD4 testing) is being scaled back for assessment of treat-
ment responses where VL testing is available, but will still 
be required for the foreseeable future in many settings to 
determine the level of HIV-induced immune deficiency, 
including the need for screening and prophylaxis for 
serious co-infections, and to prioritize initiation of HIV 
treatment. Clinical monitoring is essential for all patients 
who are receiving ART to monitor patient responses to 
treatment and diagnose potential treatment failure [8]. 
In addition, monitoring of ARV drug toxicity is recom-
mended, as delaying drug substitutions when there are 
adverse drug effects may not only cause harm but also 
result in non-adherence leading to drug resistance and 
treatment failure. The latter will compromise the effec-
tiveness of available ART regimens, increase spread of 
drug-resistant HIV, increase HIV incidence, morbidity 
and mortality and negatively impact the long-term sus-
tainability and efficacy of ART programs in LMICs.
Given the current limited health system capacity in 
many LMICs, meeting WHO’s recommendations regard-
ing regular monitoring of patients’ responses to treat-
ment, including monitoring of drug toxicity, may pose 
major challenges to the health system with possible nega-
tive impacts on quality and sustainability of HIV services 
in the future [9, 10]. This vulnerable situation is particu-
larly likely while rapid scale up of decentralized provision 
of ART is being prioritized.
This systematic review assessed the feasibility of ART 
treatment monitoring in settings of decentralized HIV 
treatment and care in LMICs.
Methods
Literature search strategy
The preferred reporting item for systematic reviews and 
meta-analysis (PRISMA statement) [11] was used to 
guide the conduct of this review. A literature search strat-
egy was developed to identify relevant studies that involve 
decentralization of HIV treatment and care in low and 
middle income countries, published in English between 
Jan 2006 and Dec 2015. Key search terms include MeSH 
and free text terms relevant to HIV infection, HIV treat-
ment and care, health service delivery models and service 
accessibility such as: “HIV”, “HIV infection”, “Antiret-
roviral therapy”, “ART”, “HAART”, “delivery of health 
care” “primary health care”, “community health services”, 
“home-based*”, “decentral*”, “task-shift*”. Search terms 
also included those that refer to treatment monitor-
ing including “treatment outcomes”, “adverse effect” and 
“toxicity”. The search strategy was first conducted in 
Medline (see Additional file 1: Annex S1), then adapted 
to run across CENTRAL, CINAHL, EMBASE, Sco-
pus and Web of science. Conference abstracts were also 
searched from International AIDS Society and CROI 
conference websites. Grey literature resources and refer-
ence lists of existing systematic reviews were searched to 
identify relevant studies. For the purpose of this review, 
“feasibility” is defined as capacity of health system to pro-
vide and patient’s accessibility to ART monitoring ser-
vices following WHO’s recommendations [7].
Study selection
Studies met inclusion criteria for this review if they: (i) 
involved HIV infected patients requiring ART and treat-
ment follow-up, and/or healthcare workers involved in 
providing ART services; (ii) involved a decentralized 
model of HIV treatment and care which was defined as 
ART initiation and/or ART monitoring services provided 
at non-hospital settings: primary health facility or com-
munity level (through home-based delivery or commu-
nity outreach including mobile health services); and (iii) 
reported one or more of the primary outcomes of interest 
as defined below.
1. Proportion of patients receiving (with data docu-
mented) CD4 count, clinical HIV staging, and/or 
HIV viral load monitoring at treatment follow-up at 
regular intervals (6 or 12 months);
2. Proportion of patients receiving ARV drug toxicity 
monitoring (clinical and/or biomedical) at treatment 
follow-up at regular intervals; and/or
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3. Reported enablers, barriers and other implementing 
issues related to monitoring of ART services, includ-
ing any of the following (a) human resources (avail-
ability and quality of clinical staff; staff competency 
training); (b) availability of, and access to, clinical, 
biochemical monitoring tools for monitoring treat-
ment response, diagnosing ARV drug toxicity, and/
or treatment failure; (c) supply chain management: 
reagents, equipment maintenance, etc. under decen-
tralized HIV care; (d) patient and provider’s attitude 
towards decentralization of HIV treatment and care.
Secondary outcomes included: (1) Proportion of 
patients with reported treatment failure, and (2) Propor-
tion of patients who switched to a second line ARV drug.
In order to be eligible for inclusion, studies must have 
been conducted in LMICs and have reported at least one 
primary outcome or provided data which allowed for cal-
culation of treatment monitoring uptake.
Data extraction and data synthesis
Data were extracted electronically using a pre-con-
structed, standardized data extraction form. Double data 
extraction with 20% duplication was performed by two 
independent reviewers. Extracted information included: 
study details (author/year, objective, design, number of 
patient enrolled), study population criteria, mode of ART 
services and outcome of interest. Data on outcomes of 
interest were grouped, presented and compared by mod-
els of service delivery (decentralized vs centralized), time 
point of treatment follow-up, and study design/study set-
ting context. Quantitative data were presented and ana-
lyzed descriptively and data across studies were pooled, 
provided study interventions and populations were suf-
ficiently similar. Qualitative data were thematically cat-
egorized using main themes relevant to the research 
questions, which emerged from data extracted.
Results
Study characteristics
The search strategy identified 5363 titles after duplicates 
were removed. Screening of titles plus abstracts with 
exclusion of clearly irrelevant studies resulted in 58 eli-
gible studies for full text review, of which 20 studies (19 
articles and one abstract [12]) met all of the inclusion cri-
teria, and were included in the review (Fig. 1).
All but one of these 20 studies were conducted in 
sub-Saharan Africa (SSA): 10 studies were from vari-
ous urban, peri-urban and rural settings in South Africa 
(SA), one study was from rural and urban Ethiopia, one 
from rural Lesotho, one from rural and urban Kenya, two 
from rural Rwanda, one from urban Mozambique, one 
from rural Zimbabwe, two from rural Swaziland, and one 
from Asia (Thailand). Only two studies were specifically 
designed to assess the coverage of HIV treatment moni-
toring services in a decentralized setting; other studies 
evaluated and reported treatment outcomes. Only one 
study reported the proportion of patients who developed 
drug toxicity and two studies provided qualitative data 
(Table 1).
HIV viral load (VL) monitoring
Twelve studies (Table 2) provided data regarding the pro-
portion of patients who received regular VL monitor-
ing, among which 11 studies reported the proportion of 
patients receiving VL monitoring at 12  months follow-
up, with a median service uptake of 86%. The highest 
coverage of virological monitoring services was reported 
from two randomized control trials (RCT) conducted in 
SA [13] and Kenya [14] with 92% (2582/2823) and 99% 
(86/87) uptake; both studies were conducted by dedi-
cated research staff who were not part of the routine clin-
ical service. The lowest reported proportion of patients 
with VL monitoring data came from a retrospective 
cohort study conducted between 2002 and 2008 in rural 
Thailand [15] with only 14.3% (22/154) of patients hav-
ing VL data available at baseline and at least one treat-
ment follow-up 12–48 months after treatment initiation. 
The authors reported that routine VL testing was not 
available, baseline VL data were available only for a sub-
set of the study participants and VL was determined at 
12 months intervals during the 48 months of study.
In four studies that reported the proportion of patients 
who received VL monitoring in both centralized and 
decentralized models of care, two studies reported a 
higher proportion of monitoring of patients attending 
centralized care (vs decentralized care): 99% (1774/1958) 
versus 91% (676/681) [16] and 29% (38/133) versus 14% 
(22/154) [15], while another two studies reported a 
similar or higher proportion of patients with access to 
VL monitoring with decentralized care (vs centralized 
care): 92% versus 90% [13] and 61% (296/482) versus 14% 
(41/289) [17]. In the two latter studies, both conducted in 
SA, the difference in service coverage between models of 
care was not discussed; however, one study [13] reported 
results of a 30  month randomized trial aimed to assess 
the effects of an outreach training program provided 
to nurses for ART initiation and prescribing at primary 
care clinics while the other [17] reported outcomes of a 
community-based, decentralized HIV services delivery 
program supported by Medecins Sans Frontieres (MSF).
Overall, studies conducted in urban settings reported 
a higher uptake of VL monitoring services: three studies 
conducted in urban HIV clinic settings in SA [16, 18, 19] 
reported more than 80% of patients had VL data available 
after 6–24 months on treatment while three other studies 
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in rural settings (two in South Africa [20, 21] and one in 
Rwanda [22]) reported 30–43% of patients had access to 
this service at 12  months follow-up although almost all 
(five of six) studies stated that VL (and CD4) was planned 
to be measured 6 monthly for all patients on ART. The 
ability of nursing staff to establish virological failure for 
timely referral and regimen switch was a concern as only 
59% of patients who demonstrated persistently elevated 
VL in two consecutive VL monitoring tests were referred 
for further treatment intervention [18]. None of the 
included studies reported on-site VL or CD4 testing.
Among 12 studies that included data regarding virolog-
ical assessment, only three studies reported the platform 
used for viral load testing (two studies with Nucli-Scens 
EasyQ HIV-1 and one study with a generic HIV VL 
platform-Biocentric) and none of these three studies 
discussed the blood sample used for VL testing (plasma 
or dried blood spot). None of the other nine studies 
reported how and where virological and/or immunologi-
cal monitoring for patients on treatment was conducted.
Clinical and immunological monitoring
The majority (15 of 20) of included studies reported 
the use of WHO clinical staging to assess and monitor 
patients’ responses to treatment (Table  2). Only three 
studies specifically provided data regarding the propor-
tion of patients who received clinical monitoring through 
decentralized HIV treatment programs. The other 12 
studies did not provide sufficient data for calculation 
of the coverage of clinical monitoring at decentralized 
settings.
One study [18] conducted in urban SA assessed the 
adherence of nursing staff at a primary health care 
clinic to national guidelines regarding monitoring and 
follow-up of HIV patients on ART. In this retrospec-
tive, cross-sectional study the authors randomly selected 
and assessed medical records of 488 patients attend-
ing the clinic from June 2011 to June 2012 and reported 
84% (412/488) and 78% (381/488) patients with clinical 
monitoring data available by June 2011 and June 2012 
respectively.
5,363 records (tle/abstract) 
screened 
7,981 records obtained in total  
482 addional records idenfied
through other sources (conference 
websites, grey literature) 
7,499 records idenfied from database 
search:  Medline (1,849), Embase 
(3,221), Scopus (485), CINAHL (467), 
Central (167), web of science (1,310) 
El
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2,618 duplicated records 
removed 
20 studies (19 arcles, 1 
abstract) included in 
systemac review 
   
   
 In
cl
ud
ed
58 full-text assessed 
for eligibility 
38 full-text excluded: 
HIV services provided 
at secondary or 
terary levels (Not 
involving decentralized 
care: 4); Studies focus 
on treatment 
outcomes (Not 
reporng outcome of 
interest: 33); Data only 
available at facility 
level (Study 
parcipants’ criteria 
were not met: 1) 
5,305 records excluded 
Fig. 1 Selection process of included studies
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Another study [14] aimed to evaluate clinical outcomes 
of patients enrolled in a community-based HIV care pro-
gram delivered by PLWHs (intervention group) as com-
pared to patients receiving standard, clinic-based care 
(control group). The reported proportions of patients 
monitored clinically at 12  months follow-up were iden-
tical for both groups, 85% (74/87) for the control group 
and 85.3% (87/102) for the intervention group. One study 
[23] reported a lower level of clinical monitoring cover-
age with 1250 (58%) and 1199 (56%) out of 2145 patients 
initiated on ART receiving clinical assessments at 6 and 
12 months follow-up, respectively.
Among 11 studies with patient follow-up periods from 
6 to 24  months, the reported proportion of patients 
with a CD4 count measurement with data recorded at 
6–12 month intervals ranged from 6 to 100%. One study 
[19] with follow-up data of up to five years reported 
that 67% (127/191) to 85% (3823/4512) of patients had 
their CD4 count measured, and 78% (148/191) to 87% 
(3932/4512) of patients having their VL measured, at 
12  month intervals. Data from this study showed that 
the proportion of patients receiving immunological and 
virological monitoring decreased over time, although the 
total number of patients in care also reduced by 96% after 
5 years on treatment (from 4512 after 12 months to 191 
after 5 years follow-up).
Two studies provided data that compared coverage of 
immunological monitoring between decentralized and 
centralized HIV care sites and both studies reported a 
higher uptake of services in the decentralized model. One 
study [17] reported 72% (348/482) of patients attending 
rural primary health care clinics versus 28% (81/289) 
attending a hospital had their CD4 count determined 
after 12 months of treatment. The authors reported that 
ART services provided at primary clinics were supported 
by Médecins Sans Frontières (MSF) with involvement of 
peer support groups to track defaulters, provide adher-
ence support, advocate for better drug supply and moni-
toring of HIV program whereas no such supports were 
provided to patients receiving care at hospital. The sec-
ond study [16] reported 95% of down-referred (decen-
tralized) patients (n  =  693) versus 81% of centralized 
patients (n = 2079) had a CD4 count (and VL) available 
at 12  months but the information on treatment moni-
toring procedure (platform used for VL testing, type 
of blood sample used and place where VL testing per-
formed) was not presented.
One study [23] aimed to assess the coverage of immu-
nological monitoring between HIV patients living in 
a semi-urban district in Zimbabwe and reported only 
21 and 8% of urban (n =  1545), and 2 and 1% of rural 
patients (n  =  600) had received CD4 testing at 6 and 
12 months follow-up, respectively. The authors reported 
that CD4 testing at rural health centers was usually 
restricted to the day of outreach visits when outreach 
staff collected blood samples in Ethylenediaminetet-
raacetic Acid (EDTA) tubes and brought the blood back 
to the district hospital for testing within 24  h. Limited 
capacity for specimen transportation within local health 
systems was noted as the main reason for the differ-
ences in access to CD4 testing between rural and urban 
patients.
Toxicity monitoring
No study reported the proportion of patients receiving 
laboratory monitoring for ARV drug toxicity at scheduled 
monitoring visits in program settings. The proportion of 
patients who changed their initial regimen (drug substi-
tution, not considered as switching to second line ART) 
due to drug toxicity was reported as ranging from 5% 
(161/3029) [13] to 29% (304/1040) [22]. One retrospec-
tive cohort study [24] reported 83.4% of all patients were 
screened for side-effects at all visits but the frequency of 
visits was not stated. A randomized controlled trial [25] 
reported 17% (68/404) and 16% (66/408) toxicity failure 
in patient groups managed by a nurse and by a doctor at 
primary care settings, respectively.
Secondary outcomes
Three studies reported the proportion of patients with 
virological failure and four studies reported the propor-
tion of patients who switched from 1st to 2nd line ART. 
The reported proportion of patients with treatment fail-
ure ranged from 14% (n =  4512) [19] to 49% (n =  488) 
[18] and the proportion of patients starting 2nd line treat-
ment was from 0.5% (n =  1040) [22] during 24 months 
follow-up to 12.2% (n = 4512) [19] at 60 months on treat-
ment. One study assessed the outcomes of routine VL 
monitoring of ART programs through a decentralized 
network of 22 primary care clinics and three reference 
facilities in Zimbabwe. These investigators reported 17% 
(551/3242) of VL tests had detectable HIV (>1000 copies/
µL) and among 288 patients with an initial detectable VL 
result, 78 patients (27%) did not receive adherence coun-
seling, 86 (30%) patients had no follow-up VL, and 15 
patients (5.2%) patients were switched to 2nd line treat-
ment, among whom four patients were switched based 
on a single detectable VL result [26].
Factors that influence the implementation and feasibility 
of decentralization
Data from included studies suggest that patients were 
supportive of decentralization of HIV treatment and care 
as it could help to improve their access to care (Table 3). 
One study [27] reported 96% (29/31) of patients inter-
viewed were ‘very satisfied’ or ‘satisfied’ with HIV 
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treatment services provided by nurses, and the main rea-
sons for this included reduced cost, receiving services 
near home and shorter queue, and being treated bet-
ter by staff. Health professionals also reported positive 
responses: nurses were comfortable, motivated, enthu-
siastic about the opportunity to be directly involved in 
providing life-saving treatment; physicians supported 
decentralization and nurse-led ART initiation as it could 
help increase ART coverage, but expressed uncertainty 
about the ability of nurses to manage and refer compli-
cated cases [28].
A number of system factors that could hinder the 
implementation and scale-up of decentralization in low-
resource settings were identified and discussed. These 
factors include: (i) Limited resources available for treat-
ment monitoring services (ii) Lack of a policy framework 
which allows non-physician staff (nurses) to initiate HIV 
treatment; (iii) increased workload (clinical and adminis-
trative) for nurses without commensurate remuneration; 
(iv) unreliable antiretroviral drug supplies due to poor 
communication, inadequate transport between phar-
macy/central dispensing unit and clinics; and (v) high 
costs associated with health worker training and moni-
toring of service quality [29, 30].
Discussion
Why treatment monitoring is important to achieve the 
90-90-90 goal
Monitoring of patients on antiretroviral treatment 
(ART), especially in the context of rapid scale up of ART 
coverage in high HIV burden and low-resource settings 
through different models of services delivery includ-
ing decentralization, is one of the most important ele-
ments to ensure effectiveness and sustainability of any 
HIV treatment and care program. The “90-90-90” goal 
aims at having 90% of HIV positive people knowing their 
infection status; 90% of those people receiving ART, and 
90% of those on ART with virologic suppression, and is 
considered a universal target needed to effectively con-
trol and ultimately end the global HIV epidemic. There 
are two key milestones that need to be achieved to make 
the last “90” target a reality. First, the majority (>90%) 
of patients on ART must have access to appropriate and 
timely ART monitoring: 12-monthly VL assessment or 
6-monthly clinical assessment and CD4 count if VL is 
not available. Second, effective treatment and well-func-
tioning patient support systems including adherence 
coaching must be in place to achieve a majority (>90%) of 
patients on ART with sustained viral suppression.
VL monitoring
WHO has recommended VL testing as the preferred 
method for monitoring the responses of patients on ART 
[8] and it has been suggested that in order to achieve the 
“90-90-90” goal, viral load monitoring should and can 
become the standard of care in LMICs with high HIV 
prevalence [31]. There is ample evidence showing that 
routine VL monitoring can provide an early and more 
accurate diagnosis of treatment failure when compared 
to clinical and immunological monitoring [32, 33], but 
evidence regarding the value of VL monitoring as com-
pared to immunological monitoring in reducing mor-
tality among patients on ART has been mixed [34–38]. 
Availability of, and access to, VL testing is still limited 
due to the requirements of expensive laboratory equip-
ment, complex sample collection and processing, and 
the need for highly trained personnel [39]. A recent 
WHO survey on availability and use of HIV diagnostics 
in LMICs found that the overall coverage of VL testing 
among patients on ART from 94 countries was 23% [40]. 
In our review, a wide range of VL monitoring coverage 
was observed. Although we found a median VL monitor-
ing coverage of 86% at 12  months follow-up, this level 
of coverage may not well reflect regular VL monitoring 
practice under decentralized HIV care models in LMICs. 
Among eight studies which reported VL monitoring 
rate of greater than 50% among patients on ART, five 
studies reported results of decentralized HIV programs 
supported by external donors such as MSF [17, 19, 26], 
Absolute Return for Kids [41], U.S. Agency for Inter-
national Development (USAID) [14], and two studies 
reported results of randomized trials in which VL testing 
was part of the funded studies in well-resourced settings 
[13, 14]. In addition, existing evidence suggests that the 
longer a patient is on ART the lower the rate of receiving 
regular VL test. Only three studies evaluated the long-
term (more than 24  months) follow-up of VL coverage 
[15, 19, 41]. Thus, further research is needed to examine 
patient retention and treatment monitoring practices 
with long-term follow-up, particularly in rural settings.
Clinical and immunological monitoring
At decentralized primary care levels in LMICs, clini-
cal and CD4 count monitoring remains a viable option 
to monitor treatment responses in settings where VL 
testing is not available. In our review, limited data were 
available to assess the feasibility and coverage of clinical 
and immunological monitoring in a decentralized model 
of HIV care, as only two studies provided data on the 
actual proportion of patients who received both clinical 
and CD4 monitoring. Of note, these are the two studies 
designed to assess treatment monitoring practice in two 
different settings, providing a contrasting picture of the 
coverage of treatment monitoring services. Differences in 
treatment monitoring coverage between these ART pro-
grams could be explained by study settings and service 
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delivery models; one in an urban, well staffed HIV clin-
ics with clinical staff on call and easy access to labora-
tory testing [18] while the other was in rural areas with 
ART service provided by outreach teams and with long 
distances for sample delivery from clinics to a labora-
tory facility located at a district hospital [23]. This finding 
highlights an important potential gap in existing knowl-
edge. It has implications related to the implementation 
of treatment monitoring in future decentralized ART 
programs, particularly in rural, resource-constraint set-
tings, as when only a minority of patients is engaged in 
an ART program where they receive regular monitoring, 
an increase in treatment failure and drug resistance can 
be foreseen.
Drug toxicity monitoring
Limited data were available to assess the feasibility of 
drug toxicity monitoring for patients on ART in decen-
tralized settings. None of the included studies reported 
the proportion of patients on ART who received lab-
oratory-based drug toxicity monitoring, but one RCT 
showed that the proportion of patients reporting toxic 
drug effects (defined as adverse events that required 
treatment interruption for >42  days) during the study 
period was higher than the total virological failure rate 
among patients on ART [25]. This finding is in line with 
results from other studies suggesting that drug toxicity 
is the most common reason for changing initial treat-
ment regimen [42, 43]. The WHO guidelines emphasize 
that laboratory monitoring is not required for treatment 
initiation. However, there are major toxicities associated 
with ARV drugs that should be monitored in all patients 
on treatment. The basic monitoring for potential toxic-
ity of drugs such as tenofovir, zidovudine and nevirapine 
require laboratory assessment of renal function, hemo-
globin, and liver enzymes, respectively. Without the 
availability of, and access to, these basic tests, monitoring 
for ART toxicity cannot be performed, and could com-
promise the long-term effectiveness and sustainability 
of the ART program. Researches have showed that HIV 
patients on ART who have regimen substitution due 
to drug toxicity/drug related adverse reactions were at 
higher risk of loss to follow-up [44, 45] which may partly 
explain the significant reduction in number of patients 
in care after five years of follow-up reported from study 
included in this review [19].
Barriers related to treatment monitoring and evaluation 
of treatment monitoring under decentralization
Technological constraints
From a technology perspective, in the absence of point of 
care (POC) testing, access to laboratory monitoring for 
patients on ART under a decentralized model of care in 
low-resource settings will likely be limited. For VL moni-
toring; until the arrival of a true point of care VL test, the 
feasibility of VL monitoring for patients received ART at 
the primary clinic level will depend on system capacity to 
collect and process a blood sample, transport the sample 
to a central laboratory for testing and return the result in 
a timely manner. For immunological monitoring, there 
are CD4 POC technologies available that can be operated 
in decentralized settings and produce reliable results for 
treatment monitoring [46]; their use has been shown to 
improve access to this alternative monitoring method and 
increases patient retention along the HIV treatment cas-
cade compared to conventional laboratory testing [47].
Human resource constraints
A lack of trained medical doctors for initiation and 
management of patients on ART has been identified as 
a major barrier for scaling up of ART programs [48, 49]. 
Task-shifting of HIV services from physician to non-phy-
sician carers has been introduced to overcome this chal-
lenge [4, 13]. From a treatment monitoring perspective, 
however, task-shifting does not come without challenges. 
Findings from our review suggest that increased clini-
cal and administrative responsibilities associated with 
provision of nurse-led ART services could further bur-
den the already-limited personnel at primary health care 
level. Primary health care staff reported their reluctance 
to put more PLWHA on treatment because of concern 
over their capacity to manage the burden of an increas-
ing number of patients on ART. The quality of treatment 
monitoring could also be a concern as nursing staff were 
unable to identify and refer all cases of treatment failure 
at decentralized settings for regimen change, even with 
the availability of two consecutive VL monitoring results 
indicating virological failure. The lower than expected 
rate of patients initiated on second line ART may rep-
resent an appropriate strategy to optimize adherence 
before switching therapy but it may also indicate clini-
cians’ lack of confidence regarding interpretation of VL 
results and second line treatment. The introduction of 
any new assay into a clinical setting requires education 
of the clinician in its interpretation; this is especially the 
case with a complicated tool such as a VL test. On the 
other hand, early switching to second line ART after a 
single detectable VL test without appropriately address-
ing non-adherence issues would potentially result in the 
unnecessary initiation of second line ART and, without 
addressing poor adherence would lead to suboptimal sec-
ond-line outcomes [50, 51]. This is an important issue of 
concern particularly in settings where treatment options 
are limited and second and third-line regimens are costly.
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Recommendations
In LMICs the challenge of limited coverage of, and access 
to, treatment monitoring services that is associated with 
decentralization of HIV treatment and care often lies 
within the health care system; therefore a comprehensive 
strategy to improve the practice of treatment monitoring 
should be considered from a health system strengthening 
perspective (Fig. 2).
In terms of service delivery, treatment and treatment 
monitoring services should ideally be delivered close to 
where the patient lives, with appropriate diagnostic tech-
nology and human resource availability at the primary 
health care level. The development and implementation of 
POC technologies to provide immunological and virologi-
cal monitoring are critically important to ensure appropri-
ate treatment monitoring, particularly with further scale 
up of HIV treatment services in decentralized settings.
The impact of future studies towards improving the 
implementation of decentralized care would benefit from 
the inclusion of some standardized targets and outcomes 
in published reports. In the absence of clearly defined 
indicators and targets, the assessment and appraisal of 
coverage and quality of treatment monitoring services 
continues to be a challenge. Given the momentum in 
scaling up ART and towards achieving the 90-90-90 tar-
get, there is a need for standardized measures that can be 
used in many upcoming researches reporting global pro-
gress towards this ambitious goal. The development and 
adoption of a specific set of processes and target indica-
tors regarding treatment monitoring could help to align 
the reporting system within different levels of health 
services provision, improve the timeliness of reporting 
results, and ensure that appropriate action is taken when 
results support particular interventions (e.g. adherence 
counseling).
Lastly, from governance and financing perspectives, it 
is obvious that if the ambitious “90-90-90” goal is to be 
achieved in 2020, the importance of treatment monitor-
ing must be emphasized equally with the importance of 
treatment coverage. Substantial resources are required to 
ensure appropriate treatment monitoring for all people 
on ART. Critical to success is the assessment of system 
Challenges in ART monitoring by WHO’s Health System Building Blocks                Consequences 
Limited availability and/or lack 
of access to Laboratory tesng 
[15, 23, 29] 
Lack of qualified medical staff to 
provide treatment & monitoring 
services [27, 28, 30] 
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system/Limited data 
availability for assessment [28] 
Limited/No availability of 
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High cost associated with 
training and monitoring quality 
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detected/increased non-adherence & 
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veness 
and sustainability of ART program  
Service 
Delivery 
Health 
workforce 
Health 
Informaon 
Health 
Technology 
Health 
Financing 
Leadership/
Governance 
Fig. 2 Health system challenges impacting access to ART monitoring (clinical/immunological, viral load and drug toxicity) based on data from 
studies included in the review
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capacity, particularly human resources and health tech-
nology in delivering treatment monitoring. This must be 
conducted as an integrated component of the decision-
making process in order to identify the optimal strategy 
to increase high quality coverage of HIV treatment and 
care services in any given specific setting. Expansion of 
ART coverage without considering system capacity for 
the provision of appropriate treatment monitoring to 
all patients will inevitably lead to more treatment fail-
ures and increased development of drug resistance, with 
resulting public health costs to address these problems. 
Therefore, the recommendation of WHO that lack of 
access to, or availability of, laboratory monitoring should 
not be a barrier in initiating patients on treatment may 
need to be revisited, as the closer we get to the second 
“90” goal of having 90% people diagnosed with HIV on 
treatment, the higher the importance of assuring that 
those patients who are on treatment are also appropri-
ately monitored, such that the last “90” goal of having 
90% people on treatment with viral suppression can be 
achieved.
Limitation
This review has some limitations that should be taken into 
account when interpreting the findings. Here, we identified 
only two studies that aimed to assess the monitoring and 
management of HIV patients. This paucity of data results 
in challenges regarding data interpretation and meant that 
we were unable to analyze and discuss differences in cov-
erage of treatment monitoring services as well as quality 
of the services. Lack of information and data from unpub-
lished government and program reports and studies pub-
lished in non-English language may contribute to limited 
data availability. Moreover, limited data from studies con-
ducted in SSA countries has made it difficult to generalize 
the findings outside the sub-Saharan African context.
Conclusions
The findings of this review suggest that there are poten-
tial major gaps in coverage and quality of treatment mon-
itoring services for HIV patients on ART. Further studies 
particularly from non-SSA countries with longer-term of 
follow up are in need to assess the feasibility of treatment 
monitoring in the context of decentralization HIV treat-
ment and care in LMICs. Significant investment in POC 
testing and, improving quality of and training for nursing 
staff to effectively manage patients on ART is required 
to improve quality of HIV treatment and care services. 
The development of a set of target program indicators 
for treatment monitoring is necessary to reinforce the 
importance of treatment monitoring in the HIV contin-
uum of care toward achievement of the 90-90-90 goal by 
the year 2020.
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